Literature DB >> 10769011

The metalloproteinase inhibitor GI5402 inhibits endotoxin-induced soluble CD27 and CD16 release in healthy humans.

P E Dekkers1, T ten Hove, F N Lauw, H R Koene, P Lumley, S J van Deventer, T van der Poll.   

Abstract

Metalloproteinases have been implicated in the cleavage of a number of cell surface immune receptors. Oral administration of the metalloproteinase inhibitor GI5402 attenuated the release of soluble CD27 and CD16 into the circulation after intravenous endotoxin injection in healthy humans.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10769011      PMCID： PMC97526          DOI： 10.1128/IAI.68.5.3036-3039.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  19 in total

1.  A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex.

Authors:  R Q Hintzen; R de Jong; C E Hack; M Chamuleau; E F de Vries; I J ten Berge; J Borst; R A van Lier
Journal:  J Immunol       Date:  1991-07-01       Impact factor: 5.422

2.  Regulation of expression of CD27, a T cell-specific member of a novel family of membrane receptors.

Authors:  R de Jong; W A Loenen; M Brouwer; L van Emmerik; E F de Vries; J Borst; R A van Lier
Journal:  J Immunol       Date:  1991-04-15       Impact factor: 5.422

3.  Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen.

Authors:  R A van Lier; J Borst; T M Vroom; H Klein; P Van Mourik; W P Zeijlemaker; C J Melief
Journal:  J Immunol       Date:  1987-09-01       Impact factor: 5.422

4.  Processing of tumour necrosis factor-alpha precursor by metalloproteinases.

Authors:  A J Gearing; P Beckett; M Christodoulou; M Churchill; J Clements; A H Davidson; A H Drummond; W A Galloway; R Gilbert; J L Gordon
Journal:  Nature       Date:  1994-08-18       Impact factor: 49.962

5.  The effect of a metalloproteinase inhibitor (GI5402) on tumor necrosis factor-alpha (TNF-alpha) and TNF-alpha receptors during human endotoxemia.

Authors:  P E Dekkers; F N Lauw; T ten Hove; A A te Velde; P Lumley; D Becherer; S J van Deventer; T van der Poll
Journal:  Blood       Date:  1999-10-01       Impact factor: 22.113

6.  Soluble Fc gamma receptor III in human plasma originates from release by neutrophils.

Authors:  T W Huizinga; M de Haas; M Kleijer; J H Nuijens; D Roos; A E von dem Borne
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

7.  Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor.

Authors:  G M McGeehan; J D Becherer; R C Bast; C M Boyer; B Champion; K M Connolly; J G Conway; P Furdon; S Karp; S Kidao
Journal:  Nature       Date:  1994-08-18       Impact factor: 49.962

8.  Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing.

Authors:  K M Mohler; P R Sleath; J N Fitzner; D P Cerretti; M Alderson; S S Kerwar; D S Torrance; C Otten-Evans; T Greenstreet; K Weerawarna
Journal:  Nature       Date:  1994-07-21       Impact factor: 49.962

9.  The CD27 membrane receptor, a lymphocyte-specific member of the nerve growth factor receptor family, gives rise to a soluble form by protein processing that does not involve receptor endocytosis.

Authors:  W A Loenen; E De Vries; L A Gravestein; R Q Hintzen; R A Van Lier; J Borst
Journal:  Eur J Immunol       Date:  1992-02       Impact factor: 5.532

10.  Expression and release of CD27 in human B-cell malignancies.

Authors:  M H van Oers; S T Pals; L M Evers; C E van der Schoot; G Koopman; J M Bonfrer; R Q Hintzen; A E von dem Borne; R A van Lier
Journal:  Blood       Date:  1993-12-01       Impact factor: 22.113
View more
  5 in total

Review 1.  Small therapeutic molecules for the treatment of inflammatory bowel disease.

Authors:  S J H van Deventer
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

2.  A place for TACE.

Authors:  S J H van Deventer
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

3.  Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects.

Authors:  A De Milito; S Aleman; R Marenzi; A Sonnerborg; D Fuchs; M Zazzi; F Chiodi; Fuchs D
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

4.  Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy.

Authors:  Q Zhou; A Gil-Krzewska; G Peruzzi; F Borrego
Journal:  Clin Exp Immunol       Date:  2013-07       Impact factor: 4.330

5.  Altered distribution of peripheral blood memory B cells in humans chronically infected with Trypanosoma cruzi.

Authors:  Esteban R Fernández; Gabriela C Olivera; Luz P Quebrada Palacio; Mariela N González; Yolanda Hernandez-Vasquez; Natalia María Sirena; María L Morán; Oscar S Ledesma Patiño; Miriam Postan
Journal:  PLoS One       Date:  2014-08-11       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.